Bli medlem
Bli medlem

Du är här


CORRECTION: MPI is issued patent in Australia

This is a correction of the announcement from 07:51 28.01.2016 CET. Reason for the correction: Wrong date
Hoersholm; January 28, 2016 - Medical Prognosis Institute A/S (MPI.CO)
(Denmark and Phoenix, AZ, USA) announced today IP Australia has issued a
Notice of Acceptance for a patent of MPI's microRNA profiles to predict
response to 70 different cancer treatments. Three months after the
publication of the Notice of Acceptance, the patent will issue.
"After obtaining a patent in the USA on our mRNA based drug response
technology, this is an important expansion of MPI's patent portfolio,
geographically as well as topically,"

said Peter Buhl Jensen, CEO.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop
tumor-derived gene signatures that may predict which cancer patients are
highly likely responders to a given anticancer product. The DRP(TM) has been
tested in 32 trials, where 26 trials showed that drug-specific DRP(TM)
Biomarkers could predict which patients had a positive effect of the
treatment. The DRP(TM) platform has also been externally validated and
published in collaboration with leading statisticians at the MD Anderson
Cancer Center. The DRP(TM) method can be used to design the Clinical
Development Plan, i.e. to select which indications are relevant for a given
anticancer drug. Further to and in addition to this, individual patients'
gene patterns can be analyzed as part of a screening procedure for a clinical
trial to ensure inclusion of those patients who have a high likelihood of
response to the drug. The DRP(TM) platform can be used in all cancer types
and has been patented for more than 60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with
cancer drug developers to apply its DRP(TM) diagnostic platform to streamline
and de-risk clinical trials and drug development via biomarker optimization,
patient stratification, and development of companion diagnostics.

For further information, please contact

Peter Buhl Jensen, CEO
Phone: +45 21 60 89 22

Certified Advisor:

Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup,

MPI is issued patent in Australia - Corrected date


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medical Prognosis Institute via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.